BALAXI

BALAXI PHARMACEUTICALS LIMITED

Listed company · ISIN INE618N01022 · NSE EQ · FV ₹2
Last price
₹23
-1.24%today
What this company does

BALAXI PHARMACEUTICALS LIMITED is a listed company. It booked ₹81 cr of revenue in its latest quarter (Q1 FY27) and kept 1.6% of sales as profit.

The Company is engaged in the business of International Wholesale Distribution in various international markets.
In the report:
42out of 100
Equitytale Health Score
Strained

Healthier than 42% of listed companies we score, on all six measures of filed financials. Each measure is ranked against the 1,201–2,858 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
46

At close. Not part of the score.

Profitability & returns18

How much profit it earns on the money it employs

Balance sheet57

How much it owes, and whether earnings cover the interest

Cash quality22

Whether reported profit actually arrives as cash

Growth & consistency23

Whether sales and profit have grown, and how steadily

Valuation65

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Is this company doing well?
not investment advice
A mixed picture
Strengths
Makes a profit
Sales up 14% vs last year
Profit up 348% vs last year
Promoters hold 66%
No promoter shares pledged
Turns profit into real cash
Watch-outs
! Thin 1.6% net margin
! Low 2.1% return on equity

What if I invest in BALAXI?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹23 -1.24%
latest close · 2026-09-17
52-wk low ₹2242 sessions so far52-wk high ₹27
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio24.0Average
LowAverageHigh
P/B ratio0.51Below book
Below bookModerateHigh
EV / EBITDA11.5Average
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity2.1%Weak
WeakFairStrong ▸15%
Return on capital4.1%Weak
WeakFairStrong
Net margin1.6%Thin
ThinDecentStrong
EBITDA margin4.5%Thin
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.22Comfortable
LowModerateHigh ▸1
Interest cover3.9×Okay
RiskyOkayStrong ▸5×
Current ratio4.05Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹127 cr
Book value
₹45
EPS
₹0.24
latest quarter
Net debt
₹41 cr
owes more than its cash
Enterprise value
₹168 cr
EBITDA
₹15 cr
annualised
EBIT
₹11 cr
annualised
Operating margin
3.5%
Return on assets
1.5%
Earnings yield
4.17%
P/S
0.39
Sales / share
₹58.5
Tax rate
37.9%
Face value
₹2
Shares
5.5 cr
Working capital
₹189 cr
Current assets
₹251 cr
Current liabilities
₹62 cr
Delivery %
73.1%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the FY 2025 report & filings
not investment advice
Hard to value confidentlyLow confidence
It earns about 3% on its capital — below the ~14% return we'd require to fund it — so a low price is likely justified, not a bargain.
Models span ₹32₹68, midpoint ₹50

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹81 cr
Other Income₹-99.2 L
Total Income₹80 cr
Cost of Materials₹43 cr
Purchases of Stock-in-Trade₹0 cr
Employee Benefit Expense₹11 cr
Finance Costs₹73.3 L
Depreciation & Amortisation₹84.9 L
Other Expenses₹21 cr
Total Expenses₹78 cr
Profit before Tax₹2 cr
Tax Expense₹79.2 L
Net Profit₹1 cr
Net margin on total income1.6%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹43 cr54.2%
Employee benefit expense₹11 cr14.3%
Finance costs₹73.3 L0.9%
Depreciation & amortisation₹84.9 L1.1%
Other expenses₹21 cr27.0%
Tax expense₹79.2 L1.0%
Profit for the period₹1 cr1.6%
Total income ₹80 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue73 cr71 cr81 cr
Total income73 cr74 cr80 cr
Expenses71 cr72 cr78 cr
Profit before tax2 cr1 cr2 cr
Tax1 cr79 L79.2 L
Net profit (owners' share)30.5 L61.3 L1 cr
Net margin (owners' share, on revenue)0.4%0.9%1.6%
EPS (₹)0.060.110.24
YoY (latest quarter): total income +15.6% · net profit +347.6%
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹337 cr
Shareholder equity
₹249 cr
parent shareholders
Total debt
₹56 cr
Cash
₹15 cr
Cash flow · H1 FY26
Operating
₹15 cr
Investing
₹-17 cr
Financing
₹1 cr
Who owns it · 2026-06-30
No pledge
Promoter
66.0%
FII / Foreign
0.0%
DII / Domestic
2.6%
Retail / others
31.4%
Promoter stake down 1.8% over the last 12 quarters.
Smart-money activity
Insider trades
SoldKUNAL MAHENDRA BHAKTA · Director50,000 · ₹1.7 cr11 Apr 24
BoughtKUNAL MAHENDRA BHAKTA · Director50,000 · ₹1.7 cr11 Apr 24
BoughtKUNAL MAHENDRA BHAKTA · Director16,000 · ₹54.1 L15 Mar 24
Bulk / block deals
BoughtRGSL INVESTMENT LVF 1 · NSE5.22 L @ ₹17.6824 Mar 26
BoughtRGSL INVESTMENT LVF 1 · NSE5.20 L @ ₹17.2423 Mar 26
BoughtMITHUN KHAITAN · NSE4.20 L @ ₹27.6231 Dec 25
Stake changes
SoldEBISU Global Opportunities Fund Limited→ 4.85% · 5.00 L3 Jun 25
SoldEBISU Global Opportunities Fund Limited→ 5.75% · 13.46 L24 Apr 25
SoldUNICO GLOBAL OPPORTUNITIES FUND LIMITED→ 0.00% · 45.78 L3 Apr 25
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 24 Aug 2026
See the official result
1
Adoption of Audited Standalone Financial Statements
Backed by 100% of shareholders other than promotersneeded 50%
34.75 L votes for, 2,020 against · 0% of mutual funds and other big investors said no
2
Adoption of Audited Consolidated Financial Statements.
Backed by 100% of shareholders other than promotersneeded 50%
34.75 L votes for, 2,020 against · 0% of mutual funds and other big investors said no
3
Re-appointment of Mrs. Minoshi Maheshwari (DIN: 01575975) as a Director, liable to retire by rotation.
Promoters had a personal stake in this
Backed by 100% of shareholders other than promotersneeded 50%
34.74 L votes for, 2,439 against · 0% of mutual funds and other big investors said no
4
Re-appointment of Ms. Akshita Ostwal (DIN: 10026552), as an Independent Director of the Company.
Backed by 100% of shareholders other than promotersneeded 75%
34.74 L votes for, 2,939 against · 0% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 3 named members
owning 66.0% between them · as of 2026-06-30
BALAXI OVERSEAS PRIVATE LIMITED63.40%
ASHISH MAHESHWARI1.64%
MINOSHI MAHESHWARI0.96%
Business done with them
FY2025 · 2 of the group
The company paid ₹80 L to companies in the promoter group last year — about 0.3% of its ₹293 cr revenue and received ₹29.4 L back from them.
Ashish Maheshwari
Other payments to them · Refer text block
also owns 1.64% of the company
₹80 L
company paid
Balaxi Overseas Private Limited
Settlement Of Liabilities On Behalf Of Entity By Related Party · Refer text block
also owns 63.40% of the company
₹29.4 L
company received

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

Money raised in Oct 2022 by selling shares to selected investors

As of Mar 2026, the company says it has spent 100% of what it set aside.

The proceeds of the preferential issue shall be utilized to meet the capital expenditure requirements to support the construction of the Company’s first pharmaceutical formulation plant, being set up at Jadcherla, Hyderabad. Further, it may be utilized to meet working capital requirements and general corporate purposes and may also utilize to undertake any additional business activities under the main objects clause of the Memorandum of Association of the Company.
100%
of what was set aside
Spent by quarter: 42%60%68%72%100% (to Mar 2026)

The amount this filing states as raised is many times the whole company’s market value, so it is almost certainly entered in the wrong unit. We show the purposes and how far along each one is, and leave the rupee figures out rather than repeat a number that cannot be right.

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.